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little effect on tumor growth.The results of
treatment with AEOL-10113 or YC-1 after
radiation therapy have potentially impor-
tant clinical implications. Further studies
are required to determine whether this
sort of sequential therapy at higher doses
can have synergistic effects leading to
tumor ablation.
Finally, the authors demonstrate that
reoxygenation of cultured cells following
hypoxia results in a dramatic increase in
GFP activity compared to hypoxia alone.
They provide evidence that this is related
to the hypoxia-induced formation of
stress granules, which sequester mRNAs
transcribed by HIF-1 and prevent their
translation until reoxygenation occurs.
This result is in contrast to many studies
that have demonstrated increased
activity of HRE-driven luciferase reporter
genes and increased secretion of
endogenous VEGF protein by tumor cell
lines exposed to continuous hypoxia. The
presence of an internal ribosomal entry
site, which allows cap-independent trans-
lation, is a feature of the mRNAs encod-
ing HIF-1α, VEGF, and possibly other
hypoxia-inducible gene products (Stein et
al., 1998). Thus, there may be two cate-
gories of hypoxia-inducible gene prod-
ucts, those that are translated during
hypoxia and those that are not translated
until reoxygenation.
The combination of mechanistic
insight into fundamental aspects of can-
cer biology and the potential therapeutic
implications makes this a remarkable
paper. One factor that may limit the
extent to which these results are applica-
ble to human cancers is that the data
were derived from tumor xenografts.
Recent studies suggest that the vascula-
ture of tumor xenografts differs signifi-
cantly from the vasculature of
spontaneously arising tumors (Ruzinova
et al., 2003). Subcutaneous injection of
cancer cells into nude mice results in the
rapid growth of a tumor, the vasculariza-
tion of which is dependent upon the
recruitment of bone marrow-derived
endothelial progenitor cells. In contrast,
the vasculature of slower-growing spon-
taneous tumors may occur primarily via
the process of angiogenesis, in which
new capillaries bud from existing host
vessels and grow into the tumor. Thus, it
will be important to replicate the findings
of Moeller et al. (2004) in a spontaneous
tumor model.
The results reported by Moeller et al.
(2004) represent an important advance
linking intratumoral hypoxia, HIF-1, EC
survival, and radiation resistance. Like all
good studies, their work generates many
provocative questions. Further studies
will determine the extent to which these
intriguing observations are relevant to
cancer patients and their treatment.
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The Trojan horse was as a clever instru-
ment of war used by the Greeks to
deceive the Trojans. Epic accounts have it
that the Greeks built a giant hollow wood-
en horse—loaded with armed soldiers—
which was delivered as a gift offering of
peace.The strategy worked when the sol-
diers quietly climbed down from the horse
and opened the city gates, thus providing
for access to and defeat of Troy after a
decade of siege by the Greek army. In
spite of its overuse (a Google search
reveals over 1.1 × 106 hits), this ancient
military analogy can perhaps be best
used to describe an antitumor approach
Engineered embryonic endothelial progenitor cells as therapeutic
Trojan horses
While the hematogenic contribution of circulating endothelial cells to tumor angiogenesis is not entirely understood, one
can exploit this phenomenon as a therapeutic strategy. In this issue of Cancer Cell, Wei et al. (2004) show that murine
embryonic endothelial progenitor cells preferentially home to sites of lung metastases, evade immunological rejection, and
can exert a bystander antitumor effect when modified to contain a suicide gene construct that activates a prodrug.
Treatment with the prodrug led to improved survival in syngeneic and nonsyngeneic tumor-bearing mouse models. The
conceptual advance put forward by this study might result in translational applications.
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reported in this issue of Cancer Cell (Wei
et al., 2004).
Could a cell system serve as a thera-
peutic Trojan horse? In theory, genetically
modified cells could even offer certain
advantages as gene therapy vectors rela-
tive to viruses. However, rigorous criteria
will certainly be applied for developing a
suitable cell-based vehicle. They include
simple harvesting procedures, tolerance
to ex vivo expansion, a high level of per-
missiveness to gene transfer, adequate
tissue tropism upon systemic introduc-
tion, and low risk of untoward cell prolifer-
ation or differentiation in patients. Usually,
transplanted foreign cells are rejected by
an immune response elicited in the host
by antigens present on the cellular graft.
As nonimmunogenic universal donor cells
(which can avoid graft rejection and/or
graft versus host disease) are not avail-
able, emphasis had until recently been
placed on various adult human cell types
such as fibroblasts, myoblasts, and
endothelial cells, mostly because they
can be easily obtained from biopsy-
derived specimens and expanded in tis-
sue culture.
In searching for suitable cells that
might be candidates for development as
gene therapy vectors, one does not have
to look very far. The field of stem cell biol-
ogy has taken tremendous strides within
the past five to ten years. Stem cells with
totipotency and self-renewal are currently
being heralded as having great promise—
as yet largely unmet—in regenerative and
therapeutic medicine (Korbling and
Estrov, 2003). Along these lines, great
interest has been focused on the develop-
ment of multipotent progenitor cells capa-
ble of participating in the formation of the
endothelium (Rafii and Lyden, 2003).
While a possible hematogenic contribu-
tion to the vasculature has long been rec-
ognized (Kennedy and Weissman, 1971),
the origin, character, and share of circulat-
ing endothelial cells during tumor angio-
genesis remain poorly defined to date.
Since the first isolation of adult
endothelial progenitor cells (Asahara et
al., 1997), many individual steps have
been put in place to allow the use of circu-
lating adult endothelial cells for therapeutic
purposes. In previous work, Hatzopoulos
and colleagues have developed a different
approach: they isolated (Hatzopoulos et
al., 1998) and characterized (Vajkoczy et
al., 2003) a population of endothelial prog-
enitor cells from mouse embryos. On an
independent line of research, Chung-Faye
et al. (2001) established a bifunctional
fusion gene construct (cytosine deami-
nase: uracil phosphoribosyltransferase) to
catalyze the stepwise conversions of the
prodrug 5-fluorocytosine (5-FC) into the
cytotoxic drug 5-fluorouracil (5-FU), and of
5-FU to its active metabolites (Figure 1A).
Together, these studies form the rationale
for using genetically modified embryonic
endothelial progenitor cells to deliver a
therapeutic gene.
To develop a cellular vehicle able to
reach angiogenic and metastatic sites
after systemic administration, Wei et al.
(2004) set out to exploit the natural tro-
pism of circulating embryonic endothelial
progenitor cells. In a proof-of-concept
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Figure 1. Antitumor therapy with genetically modified embryonic endothelial progenitor cells
A: Pathway of conversion of 5-FC into 5-FU and its active metabolites (Chung-Faye et al., 2001). The CD and UPRT enzymes are highlighted.
B: Upon treatment with the prodrug 5-FC, genetically modified embryonic endothelial progenitor cells undergo apoptosis.
C: Genetically modified embryonic endothelial progenitor cells become incorporated in tumor blood vessels and stroma after intravenous
administration (Vajkoczy et al., 2003; Hatzopoulos et al., 1998).
D: Treatment with the prodrug 5-FC triggers a local bystander effect in lung metastases of tumor mouse models (Wei et al., 2004).
We thank Michael G. Ozawa for assistance with illustrations.
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study, the authors tested whether embry-
onic endothelial progenitor cells contain-
ing a suicide gene construct would have
antitumor effects when administered sys-
temically. The embryonic endothelial
progenitor cells used by the authors have
been isolated at the onset of angio-
genesis (E7.5) of mouse development
(Hatzopoulos et al., 1998), and have been
characterized as presenting a Tie-2 posi-
tive, c-kit positive, Sca-1 positive, and Flk-
1 negative/low phenotype (Vajkoczy et al.,
2003). Because such embryonic endothe-
lial progenitor cells do not express MHC I
proteins, they appear to be “stealth” to
natural killer cytolysis, and thus can serve
as gene therapy vehicles in both syn-
geneic and nonsyngeneic mouse tumor
models. Moreover, given their apparent
self-renewal ability, embryonic endothelial
progenitor cells are a convenient reagent
for ex vivo expansion and genetic
modification. Satisfyingly, the authors
demonstrate successful treatment of lung
metastases through a complex multistep
process. First, ex vivo expanded embry-
onic endothelial progenitor cells are trans-
fected with the suicide construct to
convert 5-FC into 5-FU and its active
metabolites (Figure 1B). Second, the
engineered embryonic endothelial prog-
enitor cells were intravenously adminis-
tered into tumor-bearing mice. Third, the
cells preferentially localized to lung
metastases, where they integrated in
tumor blood vessels and extravasated into
the tumor stromal microenvironment
(Figure 1C). Fourth, upon treatment with
5-FC, protein expression of the suicide
construct in the tumors exerted a
bystander cytotoxic effect (Figure 1D) that
affected metastatic sites and slightly pro-
longed the lifespan of treated tumor-bear-
ing mice compared to controls.
On the basis of the information from
rodent systems presented by Wei et al., a
few points remain to be addressed before
this methodology can be translated into
clinical applications. For example, is there
potential for long-term eliciting of neutral-
izing antibodies secondary to exposure
to intracellular proteins, such as the sui-
cide gene product? Is there a possibility
that this approach may select for
vascularized metastases, since the less
vascularized (and therefore more hypox-
ic) metastases will be preferentially
affected? Are there ways to increase the
relatively modest effect observed in
rodent tumor models? Also, without a
plasmid drug selection in vivo, is there a
risk that mutational events might elimi-
nate the suicide genetic elements? This
reservation  is an important one, because
mice that received engineered embryonic
endothelial progenitor cells but no treat-
ment with 5-FC did actually dies sooner
than controls. And, of course, is it feasi-
ble—not only scientifically but also from a
regulatory policy viewpoint—to isolate
and use comparable human embryonic
endothelial progenitor cells?
Finally, as the authors point out, hom-
ing of embryonic endothelial progenitor
cells to lung metastases seems to rely on
a pulmonary first-pass effect. While intra-
arterial injections may circumvent this
problem and allow better access of the
embryonic endothelial progenitor cells to
metastatic sites downstream from the
lung, this would not be convenient. While
the evidence presented in Wei et al. sug-
gests that the embryonic endothelial
progenitor cells are recruited by hypoxic
metastases, it is still unclear whether
VEGF is merely a marker of hypoxia or
really serves as a functional attractant.
Indeed, the same group of investigators
have shown that E- and P-selectin and
their corresponding ligands can mediate
the homing of embryonic endothelial
progenitor cells (Vajkoczy et al., 2003),
and there is a compelling body of evi-
dence to suggest that the mechanisms of
embryonic endothelial progenitor cell
homing may vary under different condi-
tions that would change the expression of
endothelial cell surface molecules. Thus,
other genetic solutions such as the addi-
tion of targeting systems might lead to fur-
ther improvements. Homing of tumor cells
to site-specific metastases and leuko-
cytes to sites of inflammation indicates
that tissues carry unique marker mole-
cules that are selectively expressed in dif-
ferent vascular beds (Arap et al., 2002;
Fidler, 2003). The inner surfaces of blood
vessels are covered with diverse popula-
tions of endothelial cells. Phenotypes of
these cells can vary between different
organs, between different parts of the
vasculature in a given organ, and even
between neighboring endothelial cells of
the same organ and the same type of
blood vessel. The endothelium is subject-
ed to differential physiological signals,
including soluble factors (such as growth
factors, interleukins, and chemokines),
contact interactions (such as cell-cell and
cell-matrix), and other physical and chem-
ical variables (such as pH, pO2, sheer or
stretch stresses, and temperature). In
addition, there are many pathological
processes (such as inflammatory condi-
tions and malignant tumors) that dramati-
cally influence the endothelial phenotype
and may possibly affect the homing of
embryonic endothelial progenitor cells.
Identification of vascular bed-specific lig-
and-receptor pairs and knowledge of their
tissue distribution and tropism may great-
ly ameliorate the distribution and thera-
peutic profile of suicide embryonic
endothelial progenitor cells.
In summary, because embryonic
endothelial progenitor cells home to sites
of lung metastases and evade immuno-
logical rejection, they might have poten-
tial utility as vehicles for gene therapy if
properly engineered. If an improved sys-
tem can be adapted for use in patients
and survive the scientific and regulatory
scrutiny required for translation into clini-
cal applications, the promise of thera-
peutic Trojan horse cells may ultimately
be realized. If so, the work of Wei et al.
will be considered an important study
toward that milestone.
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